August 2025
1. FOURGEAUD J, Barry M, Bourgon N, Veyrenche N, et al
   Cytomegalovirus vertical transmission rate according to IgG avidity value and valacyclovir treatment of maternal primary infection in the first trimester of pregnancy.
   Clin Infect Dis. 2025 Aug 6:ciaf437. doi: 10.1093.
   

   >> Share

   
   July 2025
2. WANG L, Huang J, Jiang C, Huang M, et al
   Letermovir prophylaxis guided by cytomegalovirus cell-mediated immunity improves the outcomes of allogeneic hematopoietic stem cell transplant recipients.
   Clin Infect Dis. 2025 Jul 24:ciaf410. doi: 10.1093.
   

   >> Share

   
   May 2025
3. FUNG JST, Wright RC, Bharaj DK, Alghamdi A, et al
   Virus-specific T-cell therapy for prophylaxis and treatment of cytomegalovirus infections after transplantation: a scoping review.
   Clin Infect Dis. 2025 May 6:ciaf232. doi: 10.1093.
   

   >> Share

   
   March 2025
4. VELAPHI S, Madewell ZJ, Tippett-Barr B, Blau DM, et al
   Investigating the role of cytomegalovirus as a cause of stillbirths and child deaths in low and middle-income countries through postmortem minimally invasive tissue sampling.
   Clin Infect Dis. 2025 Mar 10:ciaf098. doi: 10.1093.
   

   >> Share

   
   November 2024
5. HELDMAN MR, Boeckh MJ, Limaye AP
   Current and future strategies for the prevention and treatment of cytomegalovirus infections in transplantation.
   Clin Infect Dis. 2024 Nov 4:ciae535. doi: 10.1093.
   

   >> Share

   
   August 2024
6. 
   Correction to: Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.
   Clin Infect Dis. 2024 Aug 2:ciae356. doi: 10.1093.
   

   >> Share

   
   July 2024
7. CUELLAR-RODRIGUEZ JM, van Duin D
   Cytomegalovirus Disease: Fine-Tuning Clinical Trial Enrollment and Standardization.
   Clin Infect Dis. 2024 Jul 29:ciae319. doi: 10.1093.
   

   >> Share

   
   
8. LJUNGMAN P, Chemaly RF, Khawaya F, Alain S, et al
   Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum.
   Clin Infect Dis. 2024 Jul 23:ciae321. doi: 10.1093.
   

   >> Share

   
   February 2024
9. HAMMOND SP, Little JS
   How much does cytomegalovirus viremia matter after chimeric antigen receptor T-cell therapy?
   Clin Infect Dis. 2024 Feb 2:ciae053. doi: 10.1093.
   

   >> Share

   
   
10. KAMPOURI E, Boeckh MJ, Hill JA
    Understanding the clinical significance of cytomegalovirus viremia after chimeric antigen receptor T-cell therapy: Should we be treating a value?
    Clin Infect Dis. 2024 Feb 2:ciae030. doi: 10.1093.
    

    >> Share

    
    January 2024
11. YATES TA, Halliday N
    Re: Association of CMV DNAemia with Long-Term Mortality in a Randomized Trial of Preemptive Therapy (PET) and Antiviral Prophylaxis (AP) for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative (D+R-) Liver Transplant Reci
    Clin Infect Dis. 2024 Jan 9:ciae004. doi: 10.1093.
    

    >> Share

    
    
12. KUMAR L, Dasgupta S, Murray-Krezan C, Singh N, et al
    Response to Yates and Halliday regarding CMV DNAemia and time-to-mortality in a Randomized Trial of PET vs AP in CMV D+R-Liver Transplant Recipients.
    Clin Infect Dis. 2024 Jan 8:ciae005. doi: 10.1093.
    

    >> Share

    
    November 2023
13. PAPANICOLAOU GA, Avery RK, Cordonnier C, Duarte RF, et al
    Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir with Valganciclovir.
    Clin Infect Dis. 2023 Nov 30:ciad709. doi: 10.1093.
    

    >> Share

    
    
14. KAMPOURI E, Ibrahimi SS, Xie H, Wong ER, et al
    CMV Reactivation and CMV-Specific Cell-Mediated Immunity after Chimeric Antigen Receptor T-Cell Therapy.
    Clin Infect Dis. 2023 Nov 17:ciad708. doi: 10.1093.
    

    >> Share

    
    October 2023
15. KUMAR L, Dasgupta S, Murray-Krezan C, Singh N, et al
    Association of CMV DNAemia with Long-Term Mortality in a Randomized Trial of Preemptive Therapy (PET) and Antiviral Prophylaxis (AP) for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative (D+R-) Liver Transplant Recipien
    Clin Infect Dis. 2023 Oct 20:ciad643. doi: 10.1093.
    

    >> Share

    
    September 2023
16. MANUEL O, Laager M, Hirzel C, Neofytos D, et al
    Immune monitoring-guided vs fixed duration of antiviral prophylaxis against cytomegalovirus in solid-organ transplant recipients. A Multicenter, Randomized Clinical Trial.
    Clin Infect Dis. 2023 Sep 22:ciad575. doi: 10.1093.
    

    >> Share

    
    
17. PORTILLO V, Masouridi-Levrat S, Royston L, Yerly S, et al
    Revisiting cytomegalovirus serology in allogeneic hematopoietic cell transplant recipients.
    Clin Infect Dis. 2023 Sep 15:ciad550. doi: 10.1093.
    

    >> Share

    
    May 2023
18. AMIR J, Chodick G, Pardo J
    Revised protocol for secondary prevention of congenital cytomegalovirus infection with valaciclovir following infection in early pregnancy.
    Clin Infect Dis. 2023 May 9:ciad230. doi: 10.1093.
    

    >> Share

    
    March 2023
19. PLOTKIN SA
    Can We Prevent Congenital Infection By Cytomegalovirus?
    Clin Infect Dis. 2023 Mar 28:ciad179. doi: 10.1093.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share